Product Suite &
Pharmaceutical Pipeline

Product Suite

Market-ready assets include management tools for advanced wound care and dermatitis. Pipeline assets include FleX™ Antimicrobial, an antimicrobial regenerative collagen powder, as well as Xeal® Silicone, a non-adherent, antimicrobial silicone dressing.

Hexagen® Antimicrobial
FDA Cleared
Xeal® Antimicrobial Wound Dressing
FDA Cleared
AtopX™ Eczema Management Tool
FDA Cleared
FleX™ Antimicrobial Collagen Matrix
510k Expected Q4 2021

Pharmaceutical Pipeline

We are engaged in the pursuit of drug therapies for the treatment of onychomycosis, herpes zoster opthalmicus, and COVID-19.

*Lead candidate

Topical Skin Infection (GX-03)*
Phase II/III Ready
Onychomycosis (TH-32)*
Phase II Ready
Intranasal COVID-19 Therapeutic (GX-03)
Clinical Trials
Herpes Zoster Ophthalmicus (HZO) (OV-02)
Animal Data